Brief: Royalty Pharma Reports Q1 2023 Results
09/05/2023 13:23
May 9 (Reuters) - Royalty Pharma PLC RPRX.O :
* ROYALTY PHARMA REPORTS FIRST QUARTER 2023 RESULTS
* ROYALTY PHARMA SAYS REAFFIRMED 2023 ADJUSTED CASH
RECEIPTS
GUIDANCE OF $2,850 TO $2,950 MILLION
Source text for Eikon: ID:nGNX1zNnwX
Further company coverage: RPRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)